Compare · DFTX vs SNDL
DFTX vs SNDL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and SNDL Inc. (SNDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SNDL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 16.9x SNDL ($356.6M).
- DFTX has been more active in the news (15 items in the past 4 weeks vs 2 for SNDL).
- DFTX has more recent analyst coverage (7 ratings vs 4 for SNDL).
- Company
- Definium Therapeutics Inc.
- SNDL Inc.
- Price
- -
- -
- Market cap
- $6.02B
- $356.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 15
- 2
- Recent ratings
- 7
- 4
SNDL
SNDL Inc.
Sundial Growers Inc. engages in production and marketing of cannabis products for the adult-use market in Canada. It produces and distributes inhalable products, such as flower, pre-rolls, and vapes. The company offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest SNDL
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Successful Completion of EU-GMP Audit at Atholville Facility
- SEC Form 6-K filed by SNDL Inc.
- SNDL Reports Second Quarter 2026 Financial and Operational Results
- SEC Form 6-K filed by SNDL Inc.
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Completion of Parallel Asset Acquisition and Positions for Nasdaq-Consolidated U.S. Medical Cannabis Operations
- SEC Form 6-K filed by SNDL Inc.
- SNDL to Report Second Quarter 2026 Financial Results on July 28, 2026
- SNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores